Luke Bi, PhD

Dr. Luke Bi joined Labcorp Bioanalytical Services in 2009 and has more than 30 years of pharmaceutical and lab management experience. Additionally, Luke previously served as a clinical pharmacology reviewer at the FDA and CDER and has extensive experience as a research scientist for prominent pharmaceutical companies.

Luke is currently head of Bioanalytical Services in China and is the author of over 20 peer-reviewed journal articles and industry presentations.

Aradhana Ghosh, MD

Dr. Aradhana Ghosh is a board-certified medical oncologist with expertise in clinical informatics and a career that has spanned both patient care and digital health. She obtained her medical degree from Albany Medical College, completed her internal medicine residency at Temple University, followed by subspecialty fellowship training in  hematology-oncology at New York Hospital - Cornell. After completing her medical training, Dr.

Labcorp's planned spin-off, Fortrea, to host 2023 Investor Day

BURLINGTON, N.C. , June 5, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp's Clinical Development and Commercialization Services business, will host its inaugural Investor Day

AMP: Association for Molecular Pathology (Europe Congress)

Changjun Yue, MD, PhD

Dr. Changjun Yue is board-certified in hematopathology, molecular genetic pathology and anatomic and clinical pathology. He has been working at Labcorp for more than 20 years. Changjun has built resilient pathologist and scientist teams in both Los Angeles and Shanghai. In his current role, he serves as the CAP/CLIA laboratory director for the Los Angeles Anatomic Pathology and Histology Center of Excellence, and has created the global Complete Pathological Response program.

Allan Watkinson, PhD

Dr. Allan Watkinson is a member of Labcorp’s Scientific Affairs team and is responsible for driving strategy and innovation in Biopharmaceutical CMC Services, as well as providing scientific support for clients. He has a BSc in biochemistry (University of Leeds) and a PhD in physiological biochemistry (Imperial College London). This was followed by 10 years of postdoctoral academic experience in research and development at the National Institutes of Health in Bethesda, Maryland, and at the University of Liverpool.

Deepak Thirunavukarasu, PhD

Dr. Deepak Thirunavukarasu is a lead scientist in the genomics department. In his current role, he is responsible for driving development and validation of qPCR, next-generation sequencing and custom genomic assays at Labcorp’s central laboratory in Indianapolis. In this role, Deepak collaborates with clients and internal teams to develop and adopt assays that fulfill client requirements.

Martin Squires

Martin Squires brings over 25 years of experience in analytical chemistry and has previously led the research and development group for Labcorp Biopharmaceutical Chemistry, Manufacturing and Control with expertise in advanced protein characterization.

Janelle Salkowitz-Bokal, MBA, PhD

Dr. Janelle Salkowitz-Bokal joined Labcorp Drug Development’s flow cytometry team as a staff scientist in 2013, after a 23-year-long career in HIV clinical trials, HIV small molecules that blocked integration and HIV vaccines. Janelle began supervising the targeted cell isolation team in 2014 due to her extensive experience in peripheral cell mononuclear cell isolation.